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Background: Circulating tumour cells (CTC) are an important indicator of metastasis and associated with a poor
prognosis. Detection sensitivity and specificity of CTC in the peripheral blood of metastatic cancer patient remain a
technical challenge.
Methods: Coherent anti-Stokes Raman scattering (CARS) microscopy was employed to examine the lipid content of
CTC isolated from the peripheral blood of metastatic prostate cancer patients. CARS microscopy was also employed
to evaluate lipid uptake and mobilization kinetics of a metastatic human prostate cancer cell line.
Results: One hundred CTC from eight metastatic prostate cancer patients exhibited strong CARS signal which arose
from intracellular lipid. In contrast, leukocytes exhibited weak CARS signal which arose mostly from cellular
membrane. On average, CARS signal intensity of prostate CTC was 7-fold higher than that of leukocytes
(P<0.0000001). When incubated with human plasma, C4-2 metastatic human prostate cancer cells exhibited rapid
lipid uptake kinetics and slow lipid mobilization kinetics. Higher expression of lipid transport proteins in C4-2 cells
compared to non-transformed RWPE-1 and non-malignant BPH-1 prostate epithelial cells further indicated strong
affinity for lipid of metastatic prostate cancer cells.
Conclusions: Intracellular lipid could serve as a biomarker for prostate CTC which could be sensitively detected
with CARS microscopy in a label-free manner. Strong affinity for lipid by metastatic prostate cancer cells could be
used to improve detection sensitivity and therapeutic targeting of prostate CTC.Background
Circulating tumour cells (CTC) are malignant cells shed
into the bloodstream. These cells spread to distant sites
where they initiate metastases, the primary cause of
cancer-specific mortality [1]. Patients with metastatic
cancers are more likely to have CTC detected in their
blood [2]. Hence, CTC are an important indicator of
metastasis and are associated with a poor prognosis [3].
Enumeration of CTC is routinely used to ascertain the
prognosis and monitor response to cancer treatments
[4]. Importantly, CTC represent an instantaneous sam-
pling of the tumour burden and thus hold the key to
understanding the stages of cancer metastasis including* Correspondence: ogoodman@roseman.edu; thuc.le@dri.edu
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reproduction in any medium, provided the orextracellular matrix degradation, tissue invasion, and es-
cape into the bloodstream [5].
Recognizing the significance of CTC, researchers
have devised a number of strategies for CTC detection
[4,6]. Four main strategies have been employed. The
first strategy focuses on capturing CTC from the blood
using either microposts or magnetic beads coated with
antibodies against epithelial cell adhesion molecule
(EpCAM) which is present in CTC of epithelial origin
but absence in leukocytes [7,8]. The second strategy
exploits the physical difference in size and density be-
tween CTC and leukocytes to separate CTC using size
exclusion filtration or density gradient centrifugation
[9-12]. The third strategy stains CTC of blood smears
using fluorescently conjugated antibodies and scans for
CTC using microscope-based cytometry [13]. The
fourth strategy detects CTC indirectly by measuring
the DNA shed by CTC into the blood using polymerased. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Mitra et al. BMC Cancer 2012, 12:540 Page 2 of 9
http://www.biomedcentral.com/1471-2407/12/540chain reaction amplification techniques [14]. Another
alternative strategy uses initial enrichment with EpCAM
molecule followed by detection with tumour specific
RT-PCR [15,16].
There are significant deficiencies with current tech-
nologies for CTC detection. While EpCAM is expressed
in most epithelial cells, the expression level varies from
cell to cell [17]. Furthermore, loss of EpCAM expression
seen in de-differentiated states such as epithelial-
mesenchymal transition and in cancer stem cells, in
which EpCAM expression may be undetectable [18,19].
Therefore, EpCAM antibodies-based enrichment meth-
ods are inadequate for the detection of CTC populations
with heterogeneous EpCAM expression levels. Second,
the heterogeneity in size, shape, and density of CTC
poses a significant challenge to their isolation based on
physical properties [20]. Third, intrinsic fluorescence
arising from nicotinamide adenine dinucleotide (NADH)
coenzymes of blood cells can interfere with the signal
arising from fluorescently-labeled CTC [21]. Fourth,
confirmatory staining for the cytoplasmic markers such
as cytokeratin requires cell fixation and does not allow
recovery of live prostate CTC for further studies [6].
Clearly, new technologies are needed to improve the de-
tection of CTC.
In this paper, we report the detection of lipid-rich
CTC in the peripheral blood of metastatic prostate can-
cer patients with coherent anti-Stokes Raman scattering
(CARS) microscopy. CARS microscopy is a label-free
and non-perturbative imaging technique highly sensitive
to the visualization of lipid-rich structures. We examine
intracellular lipid as a potential biomarker of CTC and
explore the use of CARS microscopy as a new technol-
ogy for the detection of lipid-rich CTC.
Methods
Blood sample collection and preparation
All experiments involving human subjects were per-
formed with the approval of the University Medical Cen-
ter of Southern Nevada Institutional Review Board
(FWA#0002738 and IRB#NVCI11-15) and were in com-
pliance with the World Medical Association Declaration
of Helsinki Declaration on Ethical Principles for Medical
Research Involving Human Subjects. Written informed
consent was obtained from patients prior to participa-
tion in this study. Peripheral blood from the metastatic
prostate cancer patients were collected in heparin con-
taining tubes. Metastatic cancer patients were randomly
selected for participation in this study with no bias in re-
gard to blood chemistry or clinical characteristics. Blood
of sex-age matched healthy volunteers were collected for
control. Approximately 7.5 ml of blood per patient or
volunteer was transferred into vacutainers containing
Ficoll/Hypaque solution for the collection of the buffycoats with centrifugation. After immuno-staining,
nucleated cells of the buffy coats were transferred dir-
ectly onto coverslip-bottom culture dishes and examined
with widefield fluorescence microscopy or CARS mi-
croscopy. Alternatively, to improve the detection of
CTC, the buffy coats were passed through columns con-
taining microbeads conjugated to monoclonal anti-
human CD45 antibodies (Cat. No. 130-045-801, Miltenyi
Biotec, Auburn, CA) to remove CD45-positive cells. The
flow through fractions were collected, immuno-stained
and transferred onto coverslip-bottom culture dishes for
examination with widefield fluorescence microscopy or
CARS microscopy.
Immunofluorescent staining
Cells of the buffy coats were stained with primary
antibodies against CD45 (Cat. No. ab10559, Abcam,
Cambridge, MA) and Alexa Fluor 488-conjugated second-
ary antibodies, and with primary antibodies against cyto-
keratin (CK, Cat. No. 8018, Santa Cruz Biotechnology,
Santa Cruz, CA) and TRITC-conjugated secondary anti-
bodies. The nucleus was stained with Hoeschst 33342
(Cat. No. H21492, Molecular Probes, Eugene, OR).
Immuno-staining was performed according to the manu-
facturers’ recommended protocols.
CARS microscopy and integrated Raman
microspectroscopy
The experimental setup of our home-built CARS micro-
scope has been described previously [22]. The Raman
frequency used for the detection of lipid was fixed at
2851 cm-1. Bandpass filters for Alexa Fluor 488, TRITC,
and CARS, were 510/42 nm, 579/34 nm, and 736/
128 nm, respectively. Images were acquired at 10 seconds
per frame and presented as 3-D stacks of approximately
20 frames taken at 1-micron increment along the vertical
axis. Image analysis of CARS intensity was performed
post-acquisition using NIH ImageJ software. Raw CARS
average pixel intensity (0-255) of individual cells was ana-
lyzed and used for quantitative analysis.
Cell lines and culture conditions
The non-transformed prostate epithelial cell line RWPE-1
(Cat. No. CRL-11609, ATCC, Manassas, Virginia) was
grown in the recommended keratinocyte serum free
media. The cell lines BPH-1 and C4-2 were a gift from Dr.
Simon Hayward (Vanderbilt University) and Dr. David
Nanus (Cornell University), respectively, and were both
grown in RPMI media supplemented with 10% FBS. To
evaluate lipid uptake with Oil Red O staining, cells were
incubated in 50% human plasma for 24 hours at 37oC
and 5% CO2. To track lipid uptake with CARS imaging
and Raman microspectroscopy, C4-2 cells were incu-
bated with 50% human plasma spiked with 50 μM of
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Louis, MO) for 24 hours at 37oC and 5% CO2.
RT-PCR gene expression profiling of fatty acid binding
and transport proteins
For RT-PCR profiling, total RNA extracts from cultured
cell lines were isolated using RNeasy kit (Qiagen Sample
and Assay Technologies, Valencia, CA), the DNase treat-
ment was performed on the column using the recom-
mended protocol. The cDNA was prepared with 1 μg of
starting RNA using the RT2 First Strand Kit (Qiagen,
CA). The RT2 SYBR Green ROX qPCR Mastermix
(Qiagen, CA) was used for q-PCR reactions and manu-
factures protocol was followed. The human fatty acid
metabolism array (PAHS007) from SA Biosciences
(Qiagen, CA) was used for the gene expression profiling of
fatty acid binding and transport proteins. RT-PCR data
were analyzed using the SABiosciences online analysis
software.
Results and discussion
Detection of CTC in metastatic prostate cancer patients
In the peripheral blood of metastatic prostate cancer
patients, we detected the present of Hoeschst 33342
+CD45-CK+ cells (Figure 1, upper row), which were ab-
sent in the peripheral blood of healthy volunteers. These
cells could be clearly distinguished from leukocytes,
which were Hoeschst 33342+CD45+CK- (Figure 1, lower
row). Based on previous description of CTC in the lit-
erature, CD45-CK+ cells were identified as CTC [6].
Lipid-rich prostate CTC
Previously, lipid-rich primary cancer cells and circulating
tumour cells in murine cancer model were reported withFigure 1 Detection of circulating tumour cells in the peripheral blood
identified as Hoechst33342+CD45-CK+ cells. Lower row: leukocytes were ide
widefield fluorescent microscopy.CARS imaging [23,24]. Here, we examined the lipid
content of CD45-CK+ cells with CARS microscopy.
CARS imaging, together with simultaneous two-photon
fluorescence (TPF) imaging, revealed that CD45-CK+
cells exhibited strong cytoplasmic vibrational signal at
2851 cm-1, which is a reliable measure of lipid (Figure 2,
upper row) [25]. In contrast, CD45+CK- cells exhibited
weak CARS signal at the same vibrational frequency. It
is likely that CARS signal arose mainly from cytoplas-
mic lipid accumulation in CD45-CK+ cells and from
cellular membrane in CD45+CK- cells. All 100 CTC
identified from the peripheral blood of 8 metastatic
prostate cancer patients exhibited strong CARS signal
(Figure 3A). Whereas, all leukocytes examined exhib-
ited weak CARS signal. On average, prostate CTC had
approximately 7-fold more CARS intensity than leuko-
cytes with a p-value of < 0.0000001 (Figure 3B).
High affinity for lipid by a metastatic prostate cancer cell
line
Over-expression of genes encoding for fatty acid metab-
olism and transport proteins in cancerous versus non-
transformed cells was a common observation in many
type of cancers including colorectal [26], prostate [27],
breast [28], and skin [29] cancers. Indeed, protein-
mediated lipid transport accounted for more than 90%
of cellular uptake of long-chain fatty acids [30]. To
examine the affinity of prostate cancer cells for lipid, we
employed real-time PCR to profile for the expression of
genes encoding for fatty acid transport proteins
(SLC27A1-6) and fatty acid binding proteins (FABP 1-6)
in non-transformed prostate epithelial cell line RWPE-1
[31], benign prostatic hyperplasia epithelial cell line
BPH-1 [32], and metastatic prostate cancer cell lineof metastatic prostate cancer patients. Upper row: CTC were
ntified as Hoechst33342+CD45+CK- cells. Images were taken with
Figure 2 Detection of lipid-rich prostate CTC with CARS microscopy. Upper row: Prostate CTC exhibited strong CARS signal arising from
intracellular lipid accumulation. Lower row: Leukocytes exhibited weak CARS signal arising mainly from cellular membrane.
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gene expression of 5 out of 6 fatty acid transport pro-
teins (SLC27A1, 2, 4, 5, 6) in C4-2 cells compared to
RWPE-1 and BPH-1 cells (Figure 4A). In addition, we
observed a nearly 60-fold increase in the gene expres-
sion of FABP-6 in C4-2 cells as compared to RWPE-1
and BPH-1 cells (Figure 4B). Interestingly, C4-2 cells
exhibited higher lipid uptake ability than RWPE-1 and
BPH-1 cells when incubated with 50% human plasma
for 24 hours as indicated by Oil Red O (ORO) staining
of intracellular lipid droplets (Figure 4C). Our data
revealed an increase in the expression of lipid transport
proteins and the affinity for lipid in a metastatic pros-
tate cancer cell line compared to non-transformed or
non-malignant prostate epithelial cell lines.Figure 3 Average CARS signal intensity of prostate CTC versus leukoc
cells, as a function of 100 prostate CTC (circles) and 100 leukocytes (purple
leukocytes from healthy volunteers (green squares). CTC from each individu
intensity of 100 prostate CTC from cancer patients and 200 leukocytes from
standard deviations.Lipid uptake kinetics of a metastatic prostate cancer cell
line
Taking advantage of the label-free and non-perturbative
imaging capability of CARS microscopy, we examined
the kinetics of lipid uptake of C4-2 cells following their
incubation with 50% human plasma (Figure 5A). We
found that C4-2 cells rapidly accumulated intracellular
lipid, reaching a plateau at approximately 24 hours post
incubation (Figure 6A). To confirm lipid uptake by C4-2
cells, we spiked human plasma with 50 μM of deuterated
palmitic acid and traced it with Raman microspectrome-
try. We found a distinctive carbon-deuterium vibration
peak around 2150 cm-1 arising from the intracellular
lipid of C4-2 cells (Figure 6B). Our data showed that ex-
ogenous sources of lipid indeed contributed to the rapidytes. (A) CARS intensity, average pixel intensity (0-255) of individual
squares) in eight metastatic prostate cancer patients and 100
al patient were color-coded (same color circles). (B) Average CARS
both cancer patient and healthy volunteers. Error bars are the
Figure 4 Gene expression of lipid transport proteins and lipid uptake ability. Real-time PCR gene expression profiling of (A) fatty acid
transport proteins (FATPs encoded by SLC27A genes) and (B) fatty acid binding proteins (FABPs) of non-transformed prostate epithelial cell line
RWPE-1, benign prostatic hyperplasia epithelial cell line BPH-1, and metastatic prostate cancer cell line C4-2. Gene expression levels were
normalized to 1 for RWPE-1 cell line and respectively for other cell lines. (C) Oil Red O staining to evaluate the uptake of plasma lipid by RWPE-1,
BPH-1, and C4-2 cells after 24 hours of incubation with 50% human plasma.
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with human plasma.
Lipid mobilization kinetics of a metastatic prostate cancer
cell line
Next, we examined the ability of C4-2 cells to mobilize in-
tracellular lipid following the removal of human plasma.Figure 5 Plasma lipid uptake kinetics of C4-2 metastatic prostate can
plasma as a function of time. (B) CARS intensity of individual C4-2 cells as a
versus control C4-2 cells in growth media (black squares). Error bars represeWe first incubated C4-2 cells in 50% human plasma for 4
hours, then replaced human plasma with cell culture
media and monitored intracellular lipid content with
CARS microscopy. We found that C4-2 cells had lost only
10% of their intracellular lipid at up to 24 hours after the
removal of human plasma (Figure 7A). Compare with lipid
uptake kinetics, where 100% of lipid uptake capability wascer cells. (A) CARS images of C4-2 cells incubated with 50% human
function of incubation time with 50% human plasma (red circles)
nt the standard deviations across 50 cells analyzed per time point.
Figure 6 Tracking the uptake of deuterated palmitic acid with Raman microspectroscopy. (A) CARS image of a C4-2 cell at 24 hours after
incubation with 50% human plasma spiked with 50 μM of palmitic acid d-31. Cross-hair indicates a representative location for Raman
microspectroscopy analysis. (B) Representative of Raman signatures of C4-2 cells incubated in 50% human plasma (blue) or in 50% human plasma
spiked with deuterated palmitic acid d-31 (red) for 24 hours.
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(Figure 5B), lipid mobilization kinetics of C4-2 cells oc-
curred at a much slower rate. Between 24 hours and 28
hours post plasma removal, we found a substantial drop in
intracellular lipid level of C4-2 cells of nearly 50%
(Figure 7A). However, this drop in intracellular lipid level
coincided with a doubling in C4-2 cell number
(Figure 7B). Thus, the drop in intracellular lipid level of
C4-2 cells was most likely a dilution due to cell division.
Taken together, our data showed rapid lipid uptake kinet-
ics and slow lipid mobilization kinetics by C4-2 cells.
Conclusions
Intracellular lipid as a potential biomarker for CTC
We found that all CTC identified from the peripheral
blood of metastatic prostate cancer patients were lipid-
rich. Thus, intracellular lipid can potentially serve as
an additional biomarker for prostate CTC. IncreasedFigure 7 Lipid mobilization kinetics of C4-2 metastatic prostate cance
C4-2 cells were first incubated with 50% human plasma for 4 hours, then p
represent the standard deviations across 50 cells analyzed per time point. (
of time after the removal of human plasma. Error bars are standard deviatioexpression of lipid metabolism and lipid transport pro-
teins are commonly observed in many types of cancers
[27-29]. Therefore, we anticipate that intracellular lipid
accumulation is not a property unique to CTC derived
from prostate cancer, but a general property for other
cancers as well. Indeed, we found that CTC isolated
from metastatic bladder, breast, and skin cancer patients
were also lipid rich (data not shown). In addition, intra-
cellular lipid accumulation in non-adipocyte cells is a
general defence mechanism against exposure to excess
extracellular lipid environment [24,35,36]. Therefore, we
anticipate that all CTC, and not just a specific CTC sub-
population, to exhibit intracellular lipid accumulation.
Because CARS microscopy is a label-free imaging tech-
nique highly sensitive to lipid visualization [25], it has
the potential for non-perturbative detection of CTC
based on their intracellular lipid content. However, given
the non-specificity of lipid as a biomarker, it is advisabler cells. (A) CARS intensity of individual C4-2 cells as a function of time.
lasma was removed and replaced with growth media. Error bars
B) Average C4-2 cell number per analysis area of 3 mm2 as a function
ns across 10 areas evaluated at each time point.
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specific fluorescent biomarkers to improve CTC detec-
tion sensitivity and accuracy. Fortunately, simultaneous
CARS and multicolor TPF imaging can be deployed on
any typical CARS microscope [37]. This multimodal im-
aging capability renders CARS microscopy an attractive
means for the detection of CTC. As demonstrated with
C4-2 cancer cells, the quantity of intracellular lipid is a
function of exposure time to extracellular lipid. It is
plausible that CARS signal of CTC intracellular lipid
could be used as an indicator of circulation time.
Exploring the affinity for lipid for improved detection of
CTC and delivery of anti-cancer drugs
11C-choline is commonly used in the clinic as a radiotra-
cer for positron emission tomography imaging of pros-
tate tumour due to the high affinity of prostate cancer
cells for bile acids [38]. The ability of cancer cells to up-
take natural fatty acids has also been exploited to deliver
anti-cancer drugs. Paclitaxel conjugated to docosahexae-
noic acid, or DHA-paclitaxel, has been shown to target
lung tumour implants in mice more efficiently with
increased delivery kinetics and prolonged retention time
[39]. DHA-paclitaxel, also known as Taxolprexin, is cur-
rently undergoing clinical trial for the treatment of
oesophago-gastric cancer [40]. Similarly, 5-azacytidine
conjugated to elaidic fatty acid, or compound CP-4200,
has been shown to have higher antitumour activity
than unconjugated azacytidine in an orthotopic mouse
tumour model for acute lymphocytic leukemia [41]. En-
capsulation of anti-cancer drugs in lipid emulsions has
also been shown to improve safety and delivery effi-
ciency to lung tumours in murine xenograft models
[42,43]. In agreement with the literature, we found
strong affinity for plasma lipid by C4-2 metastatic
prostate cancer cells in vitro. The detection of lipid-
rich prostate CTC in metastatic cancer patients sug-
gested a conserved affinity for lipid by metastatic
prostate cancer cells in vivo. Thus, targeting CTC
with fluorescently-conjugated fatty acids or lipophillic
anti-cancer drugs should increase the detection sensi-
tivity and therapeutic efficacy, respectively.
Other lipid-rich blood cells
In the current study, we have not observed any accumu-
lation of intracellular lipid droplets in leukocytes. How-
ever, from the literature, monocytes were reported to
uptake fatty acids from very low-density lipoprotein lip-
olysis products and formed small intracellular lipid dro-
plets [44-46]. The lipid contents of monocytes were low
overall and declined postprandially [45]. Consistent with
our observation, Wu et al reported that CD11c+ murine
wildtype monocytes lacked intracellular lipid. However,
CD11c+ monocytes from hypercholesterolemic apoE-/-knockout mice contained lipid droplets [47]. Thus,
monocytes isolated from human subjects during the
peak postprandial period may also contain lipid droplets.
It is plausible that lipid accumulation in monocytes
could be pronounced following a high-fat meal, particu-
larly in patients with dyslipidemia. Fortunately, lipid-rich
monocytes are CD45+ cells that can be readily distin-
guished from CD45- CTC. In addition, CD45+ cells can
be removed via the use of columns containing microbe-
ads conjugated to monoclonal anti-human CD45 anti-
bodies. Because labeling of CD45 surface marker can be
achieved without cell fixation, simultaneous CARS and
two-photon fluorescent imaging can be used for the de-
tection of live CTC base on positive CARS signal and
negative CD45 fluorescent signal, respectively.
Improving CTC detection throughput and sensitivity
A significant challenge to any CTC detection method is
the ability to enumerate very low number of CTC in the
blood. To achieve this goal, the detection method must
permit sampling of all individual blood cells. Currently,
the most common method for clinical CTC detection re-
lies on immuno-magnetic bead capturing system and
microscope-based cytometry [7]. In this paper, we also
used immuno-magnetic beads to reject CD45+ cell
population and enrich CTC population for subsequent
CARS imaging. However, immune-magnetic bead system
is susceptible to sample loss due to multi-step sample
preparation. Microscope-based cytometry requires all
cells to be immobilized to the glass surface for laser
scanning. This requirement is normally destructive to
cells due to high shear stress treatments. In addition, the
mechanical motions associated with microscope-stage
movements or raster scanning mirrors movements hin-
der the speed of detection. An alternative to immuno-
magnetic beads and microscope-based cytometry has
been described using microfluidic flow cytometry with a
flow rate of 1-2 ml per hour [8]. Microfluidic flow cyto-
metry generally permits higher sampling rate, less shear
stress to cells, and less sample preparation steps than
microscope-based cytometry. Previously, microfluidic
CARS flow cytometry has been employed for the enu-
meration of lipid-rich cells and particles [48]. It is con-
ceivable that the deployment of microfluidic CARS/TPF
flow cytometry to enumerate CTC will improve both
CTC detection throughput and sensitivity. High detec-
tion thoughput and large sampling volume associated
with microfluidic flow cytometry should eliminate the
need for CTC enrichment from patient blood samples.
Potential for intravital detection of CTC
In recent years, nonlinear optical (NLO) microscopy has
been increasingly employed for cancer imaging [24,49-53].
Advances in NLO endoscopy development suggest its
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ably is the development of vibrational photoacoustic
(VPA) microscopy with millimeter-scale penetration depth
that could permit label-free and bond-selective imaging of
subcutaneous microvasculature [58]. The discovery of
lipid-rich prostate CTC described in this paper suggests
possible deployment of VPA together with other NLO im-
aging modalities for intravital flow cytometry to enumer-
ate CTC in a non-invasive manner without drawing blood
[59,60].
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